PRTK VS MREO Stock Comparison

Performance

PRTK
10/100

PRTK returned -12.00% in the last 12 months. Based on SPY's performance of -7.13%, its performance is below average giving it a score of 10 of 100.

MREO
100/100

MREO returned 90.69% in the last 12 months. Based on the other stocks in its sector with an average return of -7.44%, its performance is above average giving it a grade of 100 of 100.

Analyst Price Targets

PRTK
93/100

10 analysts offer 12-month price targets for PRTK. Together, they have an average target of 20, the most optimistic target put PRTK at 20 within 12-months and the most pessimistic has PRTK at 20. These analyst ratings are from our partners at Financial Modeling Prep and Alpha Vantage.

MREO

"Analyst Price Targets" not found for MREO

Sentiment

PRTK
69/100

PRTK had a bullish sentiment score of 69.17% across Twitter and StockTwits over the last 12 months. It had an average of 8.91 posts, 3.68 comments, and 7.87 likes per day.

MREO
70/100

MREO had a bullish sentiment score of 69.97% across Twitter and StockTwits over the last 12 months. It had an average of 60.83 posts, 23.56 comments, and 139.13 likes per day.

Technicals

PRTK
86/100

PRTK receives a 85 of 100 based on 14 indicators. 11 are bullish, 1 are bearish.

MREO
18/100

MREO receives a 17 of 100 based on 14 indicators. 2 are bullish, 11 are bearish.

Earnings

PRTK
10/100

PRTK has missed earnings 7 times in the last 20 quarters.

MREO
100/100

MREO has missed earnings 1 times in the last 20 quarters.

Profit

PRTK
10/100

Out of the last 20 quarters, PRTK has had 1 profitable quarters and has increased their profits year over year on 1 of them.

MREO

"Profit" not found for MREO

Volatility

PRTK
49/100

PRTK has had a lower than average amount of volatility over the last 12 months giving it a score of 48 of 100.

MREO
45/100

MREO has had a lower than average amount of volatility over the last 12 months giving it a grade of 45 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Paratek Pharmaceuticals, Inc. Summary

Nasdaq / PRTK

Healthcare

Biotechnology

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. In addition, it has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.

Mereo BioPharma Group plc American Depositary Shares Summary

Nasdaq / MREO

Healthcare

Biotechnology

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.

Power up your portfolio